ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Review Group Urges Increased Funding For NCI AIDS Drug Discovery Program

December 3, 1999

Five Proposals Submitted In Recompetition Of FCRF Operations/Support Contract; Now Under Review

January 2, 1987

In Brief: NCAB Approves Concept Of Converting Baltimore Program To Cancer Center; New DCCP Labs Named

June 5, 1981

Freireich’s Seven Laws To Protect Against Obstacles To Clinical Research

May 14, 1976

BSA, BSC Approve Concept for NCI Scholars Program

March 7, 1997

Paulette Gray named director of NCI Division of Extramural Activities.

April 22, 2005